EGTX — Egetis Therapeutics AB (publ) Share Price
0.000.00%
Last trade - 00:00- SEK2.36bn
- SEK2.23bn
- SEK57.60m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5 | ||
| Price to Tang. Book | 37.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 37.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -54.23% | ||
| Return on Equity | -59.37% | ||
| Operating Margin | -507.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 82.56 | 40.66 | 38.24 | 22.6 | 57.6 | 57.04 | 536.58 | 15.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Directors
- Hakan Astroem CHM (73)
- Nicklas Westerholm CEO (42)
- Marie-Louise Alamaa CFO
- Jacques Nasstrom CSO (58)
- Henrik Krook VPR
- Christian Sonesson VPR
- Peter Walberg EDR
- Marie Bengtson OTH
- Dennis Henriksen OTH
- Sven Jacobsson OTH
- Malin Nittve OTH
- Kristina Nygren OTH
- Marie Ekstrom Tragardh DRC (60)
- Sten Nilsson DRC (71)
- Gunilla Osswald DRC (59)
- Elisabeth Svanberg DRC (61)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 3rd, 2006
- Public Since
- April 7th, 2011
- No. of Shareholders
- 7,143
- No. of Employees
- 30
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 292,571,459
- Address
- Klara Norra Kyrkogata 26, STOCKHOLM, 111 22
- Web
- https://www.egetis.com/
- Phone
- +46 86797210
- Contact
- Karl Hard
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for EGTX
Q3 2024 Egetis Therapeutics AB (publ) Earnings Release
Similar to EGTX
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
What is the Egetis Therapeutics AB (publ) share price?
As of Today at 20:25 UTC, shares in Egetis Therapeutics AB (publ) are trading at SEK8.08. This share price information is delayed by 15 minutes.
How has the Egetis Therapeutics AB (publ) share price performed this year?
Shares in Egetis Therapeutics AB (publ) last closed at SEK8.08 and the price had moved by +66.26% over the past 365 days. In terms of relative price strength the Egetis Therapeutics AB (publ) share price has outperformed the FTSE Global All Cap Index by +48.21% over the past year.
What are the analyst and broker recommendations for Egetis Therapeutics AB (publ)?
The overall consensus recommendation for Egetis Therapeutics AB (publ) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Egetis Therapeutics AB (publ) dividend yield?
Egetis Therapeutics AB (publ) does not currently pay a dividend.
Does Egetis Therapeutics AB (publ) pay a dividend?
Egetis Therapeutics AB (publ) does not currently pay a dividend.
When does Egetis Therapeutics AB (publ) next pay dividends?
Egetis Therapeutics AB (publ) does not currently pay a dividend.
How do I buy Egetis Therapeutics AB (publ) shares?
To buy shares in Egetis Therapeutics AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Egetis Therapeutics AB (publ)?
As of the previous close price of SEK8.08, shares in Egetis Therapeutics AB (publ) had a market capitalisation of SEK2.36bn.
Where are Egetis Therapeutics AB (publ) shares listed?
Here are the trading details for Egetis Therapeutics AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: EGTX
What kind of share is Egetis Therapeutics AB (publ)?
Based on an overall assessment of its quality, value and momentum Egetis Therapeutics AB (publ) is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Egetis Therapeutics AB (publ) share price forecast for 2024?
The analyst consensus target price for shares in Egetis Therapeutics AB (publ) is SEK15.48. That is 91.58% above the last closing price of SEK8.08.
Analysts covering Egetis Therapeutics AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -SEK1.05 for the next financial year.
What is the trend in the Egetis Therapeutics AB (publ) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Egetis Therapeutics AB (publ). Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +52.46%.
As of the last closing price of SEK8.08, shares in Egetis Therapeutics AB (publ) were trading +43.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Egetis Therapeutics AB (publ) PE Ratio?
The Egetis Therapeutics AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK8.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Egetis Therapeutics AB (publ)?
Egetis Therapeutics AB (publ)'s management team is headed by:
- Hakan Astroem - CHM
- Nicklas Westerholm - CEO
- Marie-Louise Alamaa - CFO
- Jacques Nasstrom - CSO
- Henrik Krook - VPR
- Christian Sonesson - VPR
- Peter Walberg - EDR
- Marie Bengtson - OTH
- Dennis Henriksen - OTH
- Sven Jacobsson - OTH
- Malin Nittve - OTH
- Kristina Nygren - OTH
- Marie Ekstrom Tragardh - DRC
- Sten Nilsson - DRC
- Gunilla Osswald - DRC
- Elisabeth Svanberg - DRC